Tuesday, March 3, 2015
Friday, February 27, 2015
Florida family buries 2 children from incurable disease; prays for miracle at Children's Hospital to save 9-year-old daughter
Thursday, February 26, 2015
CMMR-D/Lynch Syndrome 3-show BRAIN Tumor treatment with Temozolmide shows resistance and causes mutations that cannot be repaired!
In 2007, Scott et al44 discussed the effectiveness of chemo- therapy in patients with CMMR-D. Several cell line and mouse model studies showed that TUMORS are RESISTANT to treatment with O6-METHALATING AGENTS .18 One of these agents (TEMOZOLOMIDE) is frequently used in the standard treatment of glioblast- oma. This DRUG causes MUTATIONS in tumour DNA that CANNOT be REPAIRED by patients with a LOSS of MMR function. Indeed, investigation of a clinical specimen from a patient treated with this drug showed an ACCUMULATION of somatic MUTATIONS (mutator phenotype).45 In vitro studies showed a similar effect for busulfan but not for chloroethylating agents such as cyclo- phosphamide and melphalan.18
MSI occurs in some tumours following therapy with thiopurines or cisplatin, suggesting that MMR deficiency is important in clin- ical resistance.46–48
–51 A report on two patients with glioblastoma showed that they were resistant to treatment with temozolo- mide.52 Another study demonstrated loss of MSH6 expression in a subset of patients with glioblastoma resistant to temozolomide.53
All patients with CMMR-D known from literature with Brain tumors 36 38 43 44 52 54–58 and lymphoma38 52 57 59–63 that wertreated with chemotherapy are listed in tables 4 and 5. Most patients with T cell lymphomas showed a good response to chemotherapy. However, CHEMOTHERAPY in patients with BRAIN TUMORS had a LESS favourable outcome. In particular, only one out of six patients treated with TEMOZOLOMIDE and RADIOTHERAPY showed a partial response. In the other patients, the tumour was RESISTANT to TREATMENT.
The Congress of Neurological Surgeons has announced that Ian F. Pollack, M.D., F.A.C.S., F.A.A.P., chief, Pediatric Neurosurgery at Children’s Hospital of Pittsburgh of UPMC’s Brain Care Institute and co-director of University of Pittsburgh Cancer Institute (UPCI) Brain Tumor Program will receive the National Brain Tumor Society's Mahaley Clinical Research Award for his paper, “Peptide Vaccine Therapy for Childhood Gliomas: Interim Results of a Pilot Study.”
The award will be presented at the 2012 Congress of Neurological Surgeons annual meeting in Chicago, Oct. 6 to 10.
The first-of-its-kind study demonstrated that peptide vaccines in children with gliomas, the most common type of brain tumor, not only were well-tolerated but also showed evidence of immunological responses. Preliminary results of the study were presented at the 2012 American Association for Cancer Research Annual Meeting.
“With so many medically outstanding studies published this year in neuro-oncology, I am grateful and honored our research was selected for recognition by the Congress of Neurological Surgeons,” said Dr. Pollack, the Walter Dandy Professor of Neurological Surgery and vice chairman for academic affairs in the Department of Neurological Surgery at the University of Pittsburgh School of Medicine. “This was the first study of its type that examined peptide vaccine therapy for children with brain tumors like this, and the fact that we are now seeing tumor shrinkage is extremely encouraging in moving forward with this therapy.”
Pollack and his colleagues enrolled 32 children with gliomas, including 18 with newly diagnosed brainstem gliomas, five with newly diagnosed cerebral high-grade gliomas and nine with recurrent gliomas. Each child received serial doses of a peptide vaccine, which was designed to stimulate an immune response to a protein fragment present on their tumor cells. They are now hoping to advance this to a multicenter study within the Pediatric Brain Tumor Consortium.
The Mahaley Clinical Research Award is given at each of the American Association of Neurological Surgeons and Congress of Neurological Surgeons meetings to a neurosurgery resident, fellow, or attending who has submitted the top clinical study in neuro-oncology.
The Congress of Neurological Surgeons, a leader in education and innovation, is dedicated to advancing neurosurgery by providing members with the educational and career development opportunities they need to become leaders and innovators in the field.
For more information about Dr. Pollack, visit www.chp.edu.